Why Should You Attend:
FDA Warning Letters and recent high-profile recalls indicate major cGMP deficiencies in big name device and pharma companies. And now the FDA is taking an even tougher stance. One major failing is lack of sufficient or targeted risk-based process V&V planning / execution. Pharma companies must consider key elements of the FDA Process Validation Guidance Document; other medical products can use the same principles. Incorporate the "must have" elements from ISO 14971 and ICH Q9 for hazard analysis and product / process risk management. Then integrate all as process validation essentials and incorporate into a company's quality management system.
This webinar will review a company's process verification and validation system for major cGMP deficiencies. It will address the FDA's newer and tougher regulatory stance. Attendees will learn how the FDA's recent process validation guidance for pharma can assist all regulated industries meet regulatory requirements. It will discuss how one can start with a Master Validation Plan, evaluate its elements against ISO 14971 and ICH Q9 for hazard analysis and product risk management, allows the development of meaningful product quality-specific process validations.
It will also discuss the roles of different V&V protocols; how to employ equipment / process DQs, IQs, OQs, and PQs, or their equivalents, against a background of limited company resources. The speaker will present a matrix that simplifies "as-product", in-product", process and equipment, et al, software VT&V, assuring key FDA requirements are not overlooked. The QMS and 21 CFR Part 11 will also be discussed briefly.
Areas Covered in the Webinar:
Verification or Validation - Recent regulatory expectations
FDA's Current Process Validation Guidance
Key Process / Equipment V&V Considerations
When / How to Use DQ, IQ, OQ, PQ, ASTM E2500 Equivalents
Using the Risk Management tools of ISO 14971 and ICH Q9
The 11 Elements of the Software VT&V "Model"
Avoid recent compliance problems
FDA Warning Letters and recent high-profile recalls indicate major cGMP deficiencies in big name device and pharma companies. And now the FDA is taking an even tougher stance. One major failing is lack of sufficient or targeted risk-based process V&V planning / execution. Pharma companies must consider key elements of the FDA Process Validation Guidance Document; other medical products can use the same principles. Incorporate the "must have" elements from ISO 14971 and ICH Q9 for hazard analysis and product / process risk management. Then integrate all as process validation essentials and incorporate into a company's quality management system.
This webinar will review a company's process verification and validation system for major cGMP deficiencies. It will address the FDA's newer and tougher regulatory stance. Attendees will learn how the FDA's recent process validation guidance for pharma can assist all regulated industries meet regulatory requirements. It will discuss how one can start with a Master Validation Plan, evaluate its elements against ISO 14971 and ICH Q9 for hazard analysis and product risk management, allows the development of meaningful product quality-specific process validations.
It will also discuss the roles of different V&V protocols; how to employ equipment / process DQs, IQs, OQs, and PQs, or their equivalents, against a background of limited company resources. The speaker will present a matrix that simplifies "as-product", in-product", process and equipment, et al, software VT&V, assuring key FDA requirements are not overlooked. The QMS and 21 CFR Part 11 will also be discussed briefly.
Areas Covered in the Webinar:
Verification or Validation - Recent regulatory expectations
FDA's Current Process Validation Guidance
Key Process / Equipment V&V Considerations
When / How to Use DQ, IQ, OQ, PQ, ASTM E2500 Equivalents
Using the Risk Management tools of ISO 14971 and ICH Q9
The 11 Elements of the Software VT&V "Model"
Avoid recent compliance problems
Agenda
1. Verification or Validation -- Recent regulatory expectations
2. FDA's Current Process Validation Guidance
3. Key Process / Equipment V&V Considerations
4. When / How to Use DQ, IQ, OQ, PQ, ASTM E2500 Equivalents
5. Using the Risk Management tools of ISO 14971 and ICH Q9
6. The 11 Elements of the Software VT&V "Model"
7. Avoid recent compliance problems
